MedPath

Roche Holding AG

Roche Holding AG logo
πŸ‡¨πŸ‡­Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com
Clinical Trials
Related News

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Phase 3
Completed
Conditions
Gastric Cancer
Interventions
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Cisplatin
First Posted Date
2015-09-29
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
316
Registration Number
NCT02563054

A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants

Completed
Conditions
Healthy Volunteer
First Posted Date
2015-09-25
Last Posted Date
2017-03-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
31
Registration Number
NCT02560142
Locations
πŸ‡³πŸ‡±

PRA Health Sciences Early Development Services, Zuidlaren, Netherlands

A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer

Phase 3
Completed
Conditions
Gastric Cancer
Interventions
Drug: Capecitabine
Drug: Oxaliplatin
First Posted Date
2015-09-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1035
Registration Number
NCT02560974

A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease

Phase 3
Completed
Conditions
Pain; Bone Neoplasms; Neoplasm Metastasis
Interventions
Drug: Ibandronate
First Posted Date
2015-09-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
97
Registration Number
NCT02561039

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Completed
Conditions
Hepatitis C, Chronic
Interventions
Biological: Peginterferon alfa-2a
Drug: Ribavirin
First Posted Date
2015-09-23
Last Posted Date
2016-03-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
697
Registration Number
NCT02557646

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Biological: RO6874813
First Posted Date
2015-09-23
Last Posted Date
2018-04-04
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
120
Registration Number
NCT02558140
Locations
πŸ‡ΊπŸ‡Έ

SCRI, Nashville, Tennessee, United States

πŸ‡ͺπŸ‡Έ

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain

πŸ‡ͺπŸ‡Έ

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain

and more 1 locations

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Completed
Conditions
Hepatitis C, Chronic
Interventions
Drug: Peginterferon alfa-2a
Drug: Ribavirin
First Posted Date
2015-09-22
Last Posted Date
2016-02-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
270
Registration Number
NCT02556307

An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)

Completed
Conditions
Breast Cancer
First Posted Date
2015-09-18
Last Posted Date
2016-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
442
Registration Number
NCT02553850

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

Phase 4
Completed
Conditions
Anemia
Interventions
Drug: Epoetin beta
First Posted Date
2015-09-18
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
28
Registration Number
NCT02554942

A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants

Phase 4
Completed
Conditions
Heart Transplantation
Interventions
Drug: Daclizumab
Drug: Mycophenolate mofetil
Drug: Silrolimus
First Posted Date
2015-09-18
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
36
Registration Number
NCT02554955
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy